High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury

An L. Moens, Hunter C. Champion, Marc J. Claeys, Barbara Tavazzi, Pawel M. Kaminski, Michael S. Wolin, Dirk J. Borgonjon, Luc Van Nassauw, Azeb Haile, Muz Zviman, Djahida Bedja, Floris L. Wuyts, Rebecca S. Elsaesser, Paul Cos, Kathleen L Gabrielson, Giuseppe Lazzarino, Nazareno Paolocci, Jean Pierre Timmermans, Christiaan J. Vrints, David A Kass

Research output: Contribution to journalArticle

Abstract

BACKGROUND - The B vitamin folic acid (FA) is important to mitochondrial protein and nucleic acid synthesis, is an antioxidant, and enhances nitric oxide synthase activity. Here, we tested whether FA reduces myocardial ischemic dysfunction and postreperfusion injury. METHODS AND RESULTS - Wistar rats were pretreated with either FA (10 mg/d) or placebo for 1 week and then underwent in vivo transient left coronary artery occlusion for 30 minutes with or without 90 minutes of reperfusion (total n=131; subgroups used for various analyses). FA (4.5×10 mol/L IC) pretreatment and global ischemia/reperfusion (30 minutes/30 minutes) also were performed in vitro (n=28). After 30 minutes of ischemia, global function declined more in controls than in FA-pretreated rats (ΔdP/dtmax, -878±586 versus -1956±351 mm Hg/s placebo; P=0.03), and regional thickening was better preserved (37.3±5.3% versus 5.1±0.6% placebo; P=0.004). Anterior wall perfusion fell similarly (-78.4±9.3% versus -71.2±13.8% placebo at 30 minutes), yet myocardial high-energy phosphates ATP and ADP reduced by ischemia in controls were better preserved by FA pretreatment (ATP: control, 2740±58 nmol/g; ischemia, 947±55 nmol/g; ischemia plus FA, 1332±101 nmol/g; P=0.02). Basal oxypurines (xanthine, hypoxanthine, and urate) rose with FA pretreatment but increased less during ischemia than in controls. Ischemic superoxide generation declined (3124±280 cpm/mg FA versus 5898±474 cpm/mg placebo; P=0.001). After reperfusion, FA-treated hearts had smaller infarcts (3.8±1.2% versus 60.3±4.1% placebo area at risk; P

Original languageEnglish (US)
Pages (from-to)1810-1819
Number of pages10
JournalCirculation
Volume117
Issue number14
DOIs
StatePublished - Apr 2008

Fingerprint

Folic Acid
Ischemia
Phosphates
Wounds and Injuries
Placebos
Reperfusion
Adenosine Triphosphate
Vitamin B Complex
Hypoxanthine
Xanthine
Coronary Occlusion
Mitochondrial Proteins
Uric Acid
Nitric Oxide Synthase
Superoxides
Adenosine Diphosphate
Nucleic Acids
Wistar Rats
Coronary Vessels
Perfusion

Keywords

  • Contractility
  • Folic acid
  • Infarction
  • Ischemia
  • Nitric oxide synthase
  • Reperfusion
  • Superoxide

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury. / Moens, An L.; Champion, Hunter C.; Claeys, Marc J.; Tavazzi, Barbara; Kaminski, Pawel M.; Wolin, Michael S.; Borgonjon, Dirk J.; Van Nassauw, Luc; Haile, Azeb; Zviman, Muz; Bedja, Djahida; Wuyts, Floris L.; Elsaesser, Rebecca S.; Cos, Paul; Gabrielson, Kathleen L; Lazzarino, Giuseppe; Paolocci, Nazareno; Timmermans, Jean Pierre; Vrints, Christiaan J.; Kass, David A.

In: Circulation, Vol. 117, No. 14, 04.2008, p. 1810-1819.

Research output: Contribution to journalArticle

Moens, AL, Champion, HC, Claeys, MJ, Tavazzi, B, Kaminski, PM, Wolin, MS, Borgonjon, DJ, Van Nassauw, L, Haile, A, Zviman, M, Bedja, D, Wuyts, FL, Elsaesser, RS, Cos, P, Gabrielson, KL, Lazzarino, G, Paolocci, N, Timmermans, JP, Vrints, CJ & Kass, DA 2008, 'High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury', Circulation, vol. 117, no. 14, pp. 1810-1819. https://doi.org/10.1161/CIRCULATIONAHA.107.725481
Moens, An L. ; Champion, Hunter C. ; Claeys, Marc J. ; Tavazzi, Barbara ; Kaminski, Pawel M. ; Wolin, Michael S. ; Borgonjon, Dirk J. ; Van Nassauw, Luc ; Haile, Azeb ; Zviman, Muz ; Bedja, Djahida ; Wuyts, Floris L. ; Elsaesser, Rebecca S. ; Cos, Paul ; Gabrielson, Kathleen L ; Lazzarino, Giuseppe ; Paolocci, Nazareno ; Timmermans, Jean Pierre ; Vrints, Christiaan J. ; Kass, David A. / High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury. In: Circulation. 2008 ; Vol. 117, No. 14. pp. 1810-1819.
@article{eeb6e761c3e146778c8ccb4d145fa039,
title = "High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury",
abstract = "BACKGROUND - The B vitamin folic acid (FA) is important to mitochondrial protein and nucleic acid synthesis, is an antioxidant, and enhances nitric oxide synthase activity. Here, we tested whether FA reduces myocardial ischemic dysfunction and postreperfusion injury. METHODS AND RESULTS - Wistar rats were pretreated with either FA (10 mg/d) or placebo for 1 week and then underwent in vivo transient left coronary artery occlusion for 30 minutes with or without 90 minutes of reperfusion (total n=131; subgroups used for various analyses). FA (4.5×10 mol/L IC) pretreatment and global ischemia/reperfusion (30 minutes/30 minutes) also were performed in vitro (n=28). After 30 minutes of ischemia, global function declined more in controls than in FA-pretreated rats (ΔdP/dtmax, -878±586 versus -1956±351 mm Hg/s placebo; P=0.03), and regional thickening was better preserved (37.3±5.3{\%} versus 5.1±0.6{\%} placebo; P=0.004). Anterior wall perfusion fell similarly (-78.4±9.3{\%} versus -71.2±13.8{\%} placebo at 30 minutes), yet myocardial high-energy phosphates ATP and ADP reduced by ischemia in controls were better preserved by FA pretreatment (ATP: control, 2740±58 nmol/g; ischemia, 947±55 nmol/g; ischemia plus FA, 1332±101 nmol/g; P=0.02). Basal oxypurines (xanthine, hypoxanthine, and urate) rose with FA pretreatment but increased less during ischemia than in controls. Ischemic superoxide generation declined (3124±280 cpm/mg FA versus 5898±474 cpm/mg placebo; P=0.001). After reperfusion, FA-treated hearts had smaller infarcts (3.8±1.2{\%} versus 60.3±4.1{\%} placebo area at risk; P",
keywords = "Contractility, Folic acid, Infarction, Ischemia, Nitric oxide synthase, Reperfusion, Superoxide",
author = "Moens, {An L.} and Champion, {Hunter C.} and Claeys, {Marc J.} and Barbara Tavazzi and Kaminski, {Pawel M.} and Wolin, {Michael S.} and Borgonjon, {Dirk J.} and {Van Nassauw}, Luc and Azeb Haile and Muz Zviman and Djahida Bedja and Wuyts, {Floris L.} and Elsaesser, {Rebecca S.} and Paul Cos and Gabrielson, {Kathleen L} and Giuseppe Lazzarino and Nazareno Paolocci and Timmermans, {Jean Pierre} and Vrints, {Christiaan J.} and Kass, {David A}",
year = "2008",
month = "4",
doi = "10.1161/CIRCULATIONAHA.107.725481",
language = "English (US)",
volume = "117",
pages = "1810--1819",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "14",

}

TY - JOUR

T1 - High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury

AU - Moens, An L.

AU - Champion, Hunter C.

AU - Claeys, Marc J.

AU - Tavazzi, Barbara

AU - Kaminski, Pawel M.

AU - Wolin, Michael S.

AU - Borgonjon, Dirk J.

AU - Van Nassauw, Luc

AU - Haile, Azeb

AU - Zviman, Muz

AU - Bedja, Djahida

AU - Wuyts, Floris L.

AU - Elsaesser, Rebecca S.

AU - Cos, Paul

AU - Gabrielson, Kathleen L

AU - Lazzarino, Giuseppe

AU - Paolocci, Nazareno

AU - Timmermans, Jean Pierre

AU - Vrints, Christiaan J.

AU - Kass, David A

PY - 2008/4

Y1 - 2008/4

N2 - BACKGROUND - The B vitamin folic acid (FA) is important to mitochondrial protein and nucleic acid synthesis, is an antioxidant, and enhances nitric oxide synthase activity. Here, we tested whether FA reduces myocardial ischemic dysfunction and postreperfusion injury. METHODS AND RESULTS - Wistar rats were pretreated with either FA (10 mg/d) or placebo for 1 week and then underwent in vivo transient left coronary artery occlusion for 30 minutes with or without 90 minutes of reperfusion (total n=131; subgroups used for various analyses). FA (4.5×10 mol/L IC) pretreatment and global ischemia/reperfusion (30 minutes/30 minutes) also were performed in vitro (n=28). After 30 minutes of ischemia, global function declined more in controls than in FA-pretreated rats (ΔdP/dtmax, -878±586 versus -1956±351 mm Hg/s placebo; P=0.03), and regional thickening was better preserved (37.3±5.3% versus 5.1±0.6% placebo; P=0.004). Anterior wall perfusion fell similarly (-78.4±9.3% versus -71.2±13.8% placebo at 30 minutes), yet myocardial high-energy phosphates ATP and ADP reduced by ischemia in controls were better preserved by FA pretreatment (ATP: control, 2740±58 nmol/g; ischemia, 947±55 nmol/g; ischemia plus FA, 1332±101 nmol/g; P=0.02). Basal oxypurines (xanthine, hypoxanthine, and urate) rose with FA pretreatment but increased less during ischemia than in controls. Ischemic superoxide generation declined (3124±280 cpm/mg FA versus 5898±474 cpm/mg placebo; P=0.001). After reperfusion, FA-treated hearts had smaller infarcts (3.8±1.2% versus 60.3±4.1% placebo area at risk; P

AB - BACKGROUND - The B vitamin folic acid (FA) is important to mitochondrial protein and nucleic acid synthesis, is an antioxidant, and enhances nitric oxide synthase activity. Here, we tested whether FA reduces myocardial ischemic dysfunction and postreperfusion injury. METHODS AND RESULTS - Wistar rats were pretreated with either FA (10 mg/d) or placebo for 1 week and then underwent in vivo transient left coronary artery occlusion for 30 minutes with or without 90 minutes of reperfusion (total n=131; subgroups used for various analyses). FA (4.5×10 mol/L IC) pretreatment and global ischemia/reperfusion (30 minutes/30 minutes) also were performed in vitro (n=28). After 30 minutes of ischemia, global function declined more in controls than in FA-pretreated rats (ΔdP/dtmax, -878±586 versus -1956±351 mm Hg/s placebo; P=0.03), and regional thickening was better preserved (37.3±5.3% versus 5.1±0.6% placebo; P=0.004). Anterior wall perfusion fell similarly (-78.4±9.3% versus -71.2±13.8% placebo at 30 minutes), yet myocardial high-energy phosphates ATP and ADP reduced by ischemia in controls were better preserved by FA pretreatment (ATP: control, 2740±58 nmol/g; ischemia, 947±55 nmol/g; ischemia plus FA, 1332±101 nmol/g; P=0.02). Basal oxypurines (xanthine, hypoxanthine, and urate) rose with FA pretreatment but increased less during ischemia than in controls. Ischemic superoxide generation declined (3124±280 cpm/mg FA versus 5898±474 cpm/mg placebo; P=0.001). After reperfusion, FA-treated hearts had smaller infarcts (3.8±1.2% versus 60.3±4.1% placebo area at risk; P

KW - Contractility

KW - Folic acid

KW - Infarction

KW - Ischemia

KW - Nitric oxide synthase

KW - Reperfusion

KW - Superoxide

UR - http://www.scopus.com/inward/record.url?scp=41949135887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41949135887&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.107.725481

DO - 10.1161/CIRCULATIONAHA.107.725481

M3 - Article

VL - 117

SP - 1810

EP - 1819

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 14

ER -